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OBJECTIVES: Myeloid-derived suppressor cells contribute to the immunosuppressive microenvironment during
tumor development and limit the efficacy of cancer immunotherapy. Identifying myeloid-derived suppressor
cells and associated factors is the first step in creating strategies to reverse the suppressive effects of these cells
on the immune system.
METHODS: To induce lung cancer, we administered 2 doses of urethane to BALB/c mice and observed these
animals for 120 days. After this period, we evaluated the percentage of myeloid-derived suppressor cells in the
blood, lung and bone marrow. The expression of alpha-smooth muscle actin, transforming growth factor-b,
Toll-like receptor 2, Toll-like receptor 4, and interleukin-6 was also determined in the lung tissue.
RESULTS: Myeloid-derived suppressor cells were increased in all evaluated tissues after lung cancer
development in association with increased Toll-like receptor 4 expression and decreased interleukin-6
expression in the lung. We observed alpha-smooth muscle actin and transforming growth factor-b expression
in lung nodules.
CONCLUSIONS:We believe that the early diagnosis of cancer through determining the blood levels of myeloid-
derived suppressor cells followed by the depletion of these cells should be further investigated as a possible
approach for cancer treatment.
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& INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) in mice are
CD11b+Gr1+ cells with monocytic (CD11b+Gr1midLy6G+/2-
Ly6ChighCD49d+) and granulocytic (CD11b+Gr1highLy6G+-
Ly6CnegCD49dneg) characteristics (1). Recently, we demon-
strated that there was a significant increase in lung-
infiltrating cells 20 days after urethane injection in a
urethane-induced lung cancer mouse model. Using flow
cytometry, we observed that in control mice, less than 1% of
the lung-infiltrating cells were CD11b+Gr1+; however,
these cells accounted for 10% in mice with urethane-
induced lung cancer (2). Other researchers have shown an
increase in MDSCs during tumor development and their
immunosuppressive role. The increased number of MDSCs
in patients has been associated with metastasis and poor
prognosis (3-5). Srivastava et al. showed that Lewis lung
carcinoma (LLC) cells injected into C57BL/6 mice caused
tumor growth in association with a significant increase in
MDSCs. Treatment with anti-Gr1 or anti-Ly6G inhibited
tumor volume, tumor weight, and metastases and reduced
the number of cells expressing Gr1 in the tumor, blood,
spleen and bone marrow. Moreover, anti-Gr1 treatment
increased the frequency and function of effector NK and T
cells (6).
MDSC activation is mediated by activated T cells and
tumor stroma products, including IFN-c, ligands for Toll-
like receptors, IL-13, IL-4 and transforming growth factor-b
(1). Recently, it was shown that tumor-infiltrating myeloid
cells induce tumor resistance to cytotoxic T cells in mice and
may contribute to the limited efficacy of cancer immu-
notherapy (7).
To better understand the mechanism through which
MDSCs contribute to cancer development, we used a mouse
model of urethane-induced lung cancer and evaluated the
associated events.
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& MATERIALS AND METHODS
Eight- to 10-week-old male BALB/c mice (bred in
CEDEME/UNIFESP) were housed in cages and cared for
in accordance with the Principles of Laboratory Animal
Care (NIH publication 86-23, revised 1985) and the regula-
tions of the Brazilian Committee on Animal Experi-
mentation. The project was submitted to and approved by
the Animal Ethics Committee of UNIFESP (protocol 0117/
09).
Control mice were observed for 120 days.
Urethane mice were injected twice (i.p.) with 1.5 g/kg
urethane (Sigma Chemical Company, St Louis, MO)
dissolved in 0.9% NaCl, with an interval of 48 hours
between administrations. These mice were observed for 120
days.
Mouse evaluation
After 120 days of follow-up, the BALB/c mice were
anesthetized, and blood, lungs, and bone marrow were
harvested. The percentage of CD11b+Gr1+ cells in these
tissues was determined with flow cytometry. The lung lobes
were sectioned and used for histology, immunohistochem-
istry and Western blot analysis.
Histological analysis
The lungs were fixed in 4% buffered formalin followed by
paraffin embedding. The fixed lungs were cut into 4 mm
sections, placed on glass slides, and stained with hematox-
ylin and eosin (H&E). These sections were then reviewed by
a pathologist who was blinded to the procedures.
Nodule measurement
H&E-stained lung tissue was observed with an image
system at 500x magnification. Each nodule was photo-
graphed, and Image Pro Plus 3.0 software was used to
analyze the data. Briefly, a circle was drawn around the
nodule with an electronic pen, and the area was immedi-
ately calculated with the UHTSCSA Image Tool 3.0.
Immunohistochemistry
Lung sections (5 mm) were deparaffinized in xylene,
rehydrated in graded ethanol, and then pretreated in a
microwave (Eletrolux, SP, Brazil) with 10 mM citric acid
buffer (pH 6) for 3 cycles of 5 min each at 850 W for antigen
retrieval. The sections were preincubated with 0.3% hydro-
gen peroxidase in PBS for 5 min to inactivate endogenous
peroxidases and blocked with 5% normal goat serum in PBS
for 10 min. The specimens were then incubated with an
anti-smooth muscle alpha actin monoclonal antibody (a-
SMA; clone 1A4: M0851, Santa Cruz Biotechnology, CA,
USA) diluted 1:500. Another set of lung sections was
incubated with anti-transforming growth factor-b mono-
clonal antibody (TGF-b1; sc-146, Santa Cruz Biotechnology,
CA, USA) at 1:200. The incubation was performed overnight
at 4 C˚ and followed by two washes in PBS for 10 min.
The sections were then incubated with anti-rabbit biotin-
conjugated secondary antibody (Vector Laboratories, CA,
USA) diluted at 1:200 in PBS for 1 h. The sections were
washed twice with PBS followed by incubation with the
preformed avidin biotin complex conjugated to peroxidase
(Vector Laboratories, CA, USA) for 45 min. The bound
complexes were visualized with 0.05% 3-39-diaminobenzi-
dine (DAB) solution.
Western blotting for TLR2, TLR4, and IL-6 protein
Solubilization buffer containing 100 mM Tris, pH 7.6, 1%
Triton X-100, 0.01 mg/mL aprotinin, 2 mM PMSF, 10 mM
Na3VO4, 10 mM NaF, 10 mM Na4P2O7, and 10 mM EDTA
was added to the lungs, and the organ was sonicated. The
insoluble material was removed with centrifugation at
11,000 rpm at 4 C˚ for 30 min. The supernatant was used to
measure the protein concentration (Bradford - ELISA assay).
Protein expression was determined by loading samples
(50 mg) onto a 10% SDS-polyacrylamide gel. The proteins
were then electrotransferred from the gel to a nitrocellulose
membrane for 90 min at 120 V. To reduce non-specific
protein binding to the nitrocellulose membrane, the filter
was pre-incubated overnight at 4 C˚ in blocking buffer (5%
nonfat dry milk, 10 mM Tris, 150 mM NaCl and 0.02%
Tween 20). The nitrocellulose membranes were incubated
overnight at 4 C˚ with anti-TLR2, anti-TLR4 (Santa Cruz
Biotechnology, CA, USA), and anti-IL-6 antibodies (R&D
Systems) diluted in blocking buffer (3% nonfat dry milk,
10 mM Tris, 150 mM NaCl and 0.02% Tween 20). The
membranes were then incubated with secondary antibody
conjugated to horseradish peroxidase diluted in blocking
buffer (1% nonfat dry milk, 10 mM Tris, 150 mM NaCl and
0.02% Tween 20) for 60 min. To visualize the proteins,
enhanced chemiluminescence reagents were used, and the
membranes were exposed to pre-flashed Kodak XAR film
(Eastman Kodak, Rochester, NY). Quantitative analysis was
performed with Scion Image software (Frederick, MD,
USA).
Statistical analysis
The results are shown in graphical form as the mean ¡
standard error. A non-parametric Mann Whitney test was
performed for group comparisons, and differences were
considered significant at p,0.05.
& RESULTS
The percentage of myeloid-derived suppressor cells
(CD11b+Gr1+) was increased in the blood, lung and bone
marrow of urethane-treated mice 120 days after cancer
induction (Figure 1). Moreover, the absolute number of
CD11b+Gr1+ cells was higher in the blood and lungs of mice
from the urethane group compared to the control group. In
urethane-treated mice, the area of the lung nodules ranged
from 7998.90 mm2 to 22595.76 mm2, whereas the control
mice had no lung nodules or hyperplasia (Table 1). Figure 2
shows a-SMA expression in the lung tissue. This marker is
characteristic of differentiated myofibroblasts in tumor
microenvironments but can also be expressed in vessels.
Urethane-treated mice expressed a-SMA in the stroma and
vessels of lung nodules (Figures 2C and 2D). Lungs from the
urethane-treated mice exhibited higher TLR4 protein
expression than the control group (control = 1.4¡0.7,
urethane = 3.0¡0.6). TLR2 protein expression in lung tissue
was similar between the groups (control = 0.74¡0.07,
urethane = 0.72¡0.04), and IL-6 protein expression was
decreased in the urethane-treated group (control = 0.61
¡0.13, urethane = 0.21¡0.04; Figures 3A-C). TGF-b was
strongly expressed in the lung bronchiole epithelium of
mice in both the control and urethane groups. TGF-b
expression was also observed in the lung nodules (Figure 4
A-D).
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Figure 1 - Evaluation of BALB/c mice at 120 days after urethane (n= 4) injection versus the control (n=4) mice. The urethane-treated
mice showed an increase in the absolute cell number of CD11b+Gr-1+ cells (myeloid derived suppressor cells, MDSCs, p =0.0571) in the
lung and a higher percentage of MDSCs in the bone marrow (p=0.0765). A representative dot plot of the flow cytometry results (J, K).
Myeloid-derived suppressor cells in lung cancer




Consistent with our previous results (2,8,9), all mice
injected with urethane in this study developed lung nodules
and showed an increase in MDSCs. The increase in MDSCs
has been associated with immune system modulation that
favors tumor growth. Notably, we observed that the control
mice also presented with some MDSCs in the blood, lung,
and bone marrow after 120 days (16-week-old mice) of
follow-up. The lungs of the control mice contained 5.7%
MDSCs, whereas our previous study showed that after 20
days (8- to 9-week-old mice) of follow-up, the control mice
had less than 1% MDSCs in the lung (2). We hypothesize
that this difference is because of ageing. This finding is
consistent with Enioutina et al. (10), who showed an
increase in CD11b+Gr1+ cells in the spleen, peripheral
lymph nodes, bone marrow and blood of old mice
compared with young mice. The increase in MDSCs because
of the ageing process could contribute to the development of
lung nodules after urethane administration.
Components of the microenvironment play an important
role during tumor development. Tumor-infiltrating myofi-
broblasts facilitate tumor growth, invasion and metastasis
by secreting growth factors and cytokines, and they also
Table 1 - Evaluation of lung nodules in BALB/c mice. The
control mice had no nodules and the urethane-treated
mice had an average of 5 nodules after 120 days.
Groups Number of nodules Area of nodules
Control (n = 5) 0 0
Urethane (n = 5) 5.25¡0.96 14,570¡1,790 mm2
Figure 2 - Histology and immunohistochemistry performed on the lungs of BALB/c mice at 4 months after urethane administration. A
representative lung from a urethane-treated mouse showing a nodule after 4 months of follow-up (A, 100x). Global view of a lung
nodule showing a-smooth muscle actin expression (B, 400x) and more detail of this expression in a vessel (C, 1000x) and tumor cell (D,
1000x). Lung from a representative control mouse showing a-smooth muscle actin expression in a vessel (E, 1000x).
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produce matrix and matrix-associated molecules (11-13).
Horie et al. (14) observed that cultured fibroblasts from
patients with resected lung cancer stroma (CAFs) had a
higher expression of a-SMA than normal fibroblasts.
Consistent with this finding, we observed a-SMA expres-
sion in the vessels and tumor stroma of urethane-treated
Figure 3 - Lung tissue from the control (n=3) and urethane (n=4) groups evaluated with western blotting for TLR2 (A), TLR4 (B) and IL-
6 (C) expression. TLR4 expression is increased in the lung from urethane-treated mice. IL-6 expression is higher in the lungs from control
mice. A representative blot of each protein indicates the ratios of TLR2 and fibronectin (D), TLR4 and fibronectin (E), and IL-6 and
tubulin (F).
Figure 4 - Immunostaining of TGF-b in the lungs from control mice (A, 200x) showing intense positivity in the bronchiole epithelium,
and lungs from urethane-treated mice showing positive staining in the bronchioles and nodule (B, 100x). Details of the staining for
TGF-b in the lung nodule (C, 400x) and bronchiole epithelium (D, 400x).
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mice, whereas in the control mice, a-SMA was expressed
only in the vessels (Figure 2). Nazareth et al. (15) showed
that fibroblasts from fresh lung tumor biopsy tissues
produced TGF-b1 in the majority of samples tested (7 of
8), whereas only 2 tumor cell samples were positive for this
marker, and the lymphocytes were negative. TGF-b1 has
been implicated, at least in part, in the hyporesponsiveness
of T cells in human non-small cell lung cancer (16). In our
model, a-SMA expression in lung nodules suggests the
presence of myofibroblasts, which may produce modulators
that suppress the immune system and render the tumor
microenvironment even more suppressive. Confirming our
hypothesis, we observed TGF-b1 expression in the lung
nodules of urethane-treated mice, whereas the bronchiole
epithelium was positive for this marker in both the control
and urethane-treated groups.
Tumor development is the result of several factors that act
in the immune system (effectors versus suppressors).
Inflammation regulates some of these factors and is
associated with tumor growth. Bunt et al. (17) evaluated
cells from BALB/c mice with 4T1 tumors stimulated with
IL-1b to promote a pro-inflammatory microenvironment.
BALB/c macrophages co-cultured with MDSCs and treated
with both LPS and IFN-c produced high levels of IL-10,
even in the absence of MDSCs. Mice deficient in TLR4
produced no IL-10 and were not effective in reducing IL-12
production by macrophages. The authors concluded that
TLR4 is a potential target for intervention in MDSC
activation and immune system suppression. In a metastatic
breast tumor model, Ahmed et al. (18) showed that the
number of metastatic lung nodules was higher in TLR4-/-
mice, whereas TLR4 knockdown in tumor cells (4T1) caused
a relative reduction in lung metastasis. The authors con-
cluded that TLR4 may play a defensive role at the level of the
host and a negative role at the level of the cancer. Consistent
with this finding, we observed that urethane-treated mice
had higher levels of TLR4 at the tumor site (lung tissue)
compared to the control mice. This finding was associated
with a significant increase in the absolute number of
CD11b+Gr1+ cells in the lungs of the urethane-treated group.
Notably, we found a significant decrease in IL-6 protein in
lung tissue from urethane-treated mice compared to the
control animals. IL-6 is both an inducer and a product of
MDSCs (19); therefore, we expected to observe an increase
in this cytokine after cancer development. However,
because we did not measure IL-6 levels in the other sites,
it is not possible to confirm whether this cytokine was
increased in the serum or spleen cells. In addition, several
reports have shown an increase in circulating IL-6 during
cancer development (20,21).
Cheng et al. (22) showed an associative role for TLR4, IL-
6, and TGF-b1 in tumor progression in human cervical cancer
cells and HeLa cells. They observed TLR4 overexpression in
cervical cancer cells, whereas HeLa cells treated with LPS
showed TLR4 activation and developed anti-apoptotic and
proliferative processes that were associated with IL-6 and
TGF-b1 production. Bierie & Moses suggested that the
regulation of tumorigenesis, including carcinoma initia-
tion, progression and metastasis, by TGF-b signaling
depends on its effects on both the tumor and host cell
populations (23). Tumor-infiltrating myeloid-derived sup-
pressor cells produce more TGF-b and play a suppressive
role on host immune cells, thereby promoting tumor
growth (24).
Srivastava et al. (6) showed that removing MDSCs from
murine cancer improves antitumor immune responses and
leads to significant tumor growth inhibition. In conclusion,
we believe that the early diagnosis of cancer through
determining the blood levels of myeloid-derived suppressor
cells followed by the depletion of these cells should be further
investigated as a possible approach for cancer treatment.
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